Calliditas Therapeutics AB (publ) (CALT)

Market Cap	1.10B
Revenue (ttm)	151.09M
Net Income (ttm)	-45.32M
Shares Out	54.01M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	24.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,795
Open	40.00
Previous Close	40.04
Day's Range	40.00 - 43.00
52-Week Range	15.25 - 43.00
Beta	1.46
Analysts	Hold
Price Target	39.25 (-1.88%)
Earnings Date	Nov 11, 2024

About CALT

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 217
• Stock Exchange: NASDAQ
• Ticker Symbol: CALT
• Website: https://www.calliditas.se

Financial Performance

In 2023, CALT's revenue was 1.21 billion, an increase of 50.32% compared to the previous year's 802.88 million. Losses were -466.19 million, 13.1% more than in 2022.

Financial numbers in SEK

Analyst Forecast

According to 4 analysts, the average rating for CALT stock is "Hold." The 12-month stock price forecast is $39.25, which is a decrease of -1.88% from the latest price.

Price Target

$39.25

(-1.88% downside)

Analyst Consensus: Hold